How to buy Immatics N-V stock | $11.23

Immatics N.V is a biotechnology business based in the US. Immatics N-V shares (IMTX) are listed on the NASDAQ and all prices are listed in US Dollars. Immatics N-V employs 285 staff and has a trailing 12-month revenue of around 0.00.

Immatics N-V stock price (NASDAQ: IMTX)

Use our graph to track the performance of IMTX stocks over time.

Immatics N-V shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$11.23
52-week range	$8.67 - $15.59
50-day moving average	$11.98
200-day moving average	$11.60
Wall St. target price	$24.17
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.08

Buy Immatics N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Immatics N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Immatics N.V by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Immatics N-V price performance over time

Historical closes compared with the close of $11.23 from 2021-05-28

1 week (2021-07-19)	N/A
1 month (2021-06-30)	-3.27%
3 months (2021-04-30)	-8.10%
6 months (2021-01-26)	N/A

1 year (2020-07-26)	N/A
2 years (2019-07-26)	N/A
3 years (2018-07-26)	N/A
5 years (2016-07-26)	N/A

Immatics N-V financials

Revenue TTM	$31.6 million
Gross profit TTM	$-35,832,000
Return on assets TTM	-28.6%
Return on equity TTM	-1111.57%
Profit margin	0%
Book value	$1.49
Market capitalisation	$768.1 million

TTM: trailing 12 months

Shorting Immatics N-V shares

There are currently 1.9 million Immatics N-V shares held short by investors – that's known as Immatics N-V's "short interest". This figure is 1.7% up from 1.9 million last month.

There are a few different ways that this level of interest in shorting Immatics N-V shares can be evaluated.

Immatics N-V's "short interest ratio" (SIR)

Immatics N-V's "short interest ratio" (SIR) is the quantity of Immatics N-V shares currently shorted divided by the average quantity of Immatics N-V shares traded daily (recently around 92293.34939759). Immatics N-V's SIR currently stands at 20.75. In other words for every 100,000 Immatics N-V shares traded daily on the market, roughly 20750 shares are currently held short.

However Immatics N-V's short interest can also be evaluated against the total number of Immatics N-V shares, or, against the total number of tradable Immatics N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Immatics N-V's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Immatics N-V shares in existence, roughly 30 shares are currently held short) or 0.067% of the tradable shares (for every 100,000 tradable Immatics N-V shares, roughly 67 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Immatics N-V.

Find out more about how you can short Immatics N-V stock.

Immatics N-V share dividends

We're not expecting Immatics N-V to pay a dividend over the next 12 months.

Immatics N-V overview

Immatics N. V. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, an anti-tumor therapy, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies includes IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid tumors. It also develops IMA101, a multi-target precision immunotherapy; and IMA301, an allogenic cellular therapy product candidate.

Frequently asked questions

What percentage of Immatics N-V is owned by insiders or institutions?
Currently 40.634% of Immatics N-V shares are held by insiders and 41.411% by institutions. How many people work for Immatics N-V?
Latest data suggests 285 work at Immatics N-V. When does the fiscal year end for Immatics N-V?
Immatics N-V's fiscal year ends in December. Where is Immatics N-V based?
Immatics N-V's address is: Paul-Ehrlich-Strasse 15, Tübingen, Germany, 72076 What is Immatics N-V's ISIN number?
Immatics N-V's international securities identification number is: NL0015285941